rafal_olechowski
Vaxcyte (Nasdaq: PCVX) announced a long -term agreement of a value of up to $ 1 billion with thermo fisher Scientific (NYSE: TMO) Tuesday to support the future commercial production of its pneumonia vaccines.
Under the agreement, which Vaxcyte (Nasdaq: PCVX) cited as a key component in
